Dr. Hieronymus received a PhD from Harvard University, focusing on the functional regulatory role of co-transcriptional gene expression processes.  Dr. Hieronymus subsequently was a Damon Runyon post-doctoral fellowship at the Broad Institute of Harvard and MIT, identifying mechanistic effects of small molecule drugs on nuclear hormone signaling through in silico analysis.  Dr. Hieronymus has lead several cancer genomic efforts as a Senior Scientist at Memorial Sloan Kettering, including work demonstrating that the burden of copy number alteration in prostate cancer genomes is prognostic for cancer relapse and metastasis.  Dr. Hieronymus has been broadly involved in applying genetic and genomic data from human cohorts, as well as in vitro and mouse model systems, to cancer growth and therapeutic resistance.